NEW YORK (Reuters Health)—Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. The prospective study, published online Jan. 8 in Rheumatology, evaluated the response to either pneumococcal conjugate vaccine (PCV13) or… [Read More]
Search results for: Pneumococcal Vaccine
How Immunosuppression May Affect COVID-19 Vaccine Response

Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immunosuppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing… [Read More]
The ACR Addresses Vaccine Challenges

An ACR COVID-19 Vaccine task force examined vaccine data and literature to evaluate COVID-19 vaccine safety, efficacy and interaction with medications for patients with rheumatic and musculoskeletal diseases, and to craft a living guidance document for members.... [Read More]
IBD Tied to Higher Risk of Invasive Pneumococcal Disease
NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) are at slightly increased risk of invasive pneumococcal disease (IPD), according to Danish researchers. In a paper online Sept. 8 in The American Journal of Gastroenterology, Bjørn Kantsø of Statens Serum Institut in Copenhagen and colleagues note that the inappropriate immune response against infective agents seen in… [Read More]
Project Increases Pneumococcal Vaccination Rates in Rheumatology Patients
NEW YORK (Reuters Health)—A multicomponent intervention can significantly increase pneumococcal vaccination rates in pediatric rheumatology patients, researchers report. “The interventions outlined in our article can easily be implemented in pediatric rheumatology practices or other subspecialty clinics,” Dr. Julia G. Harris from Children’s Mercy Hospital, Kansas City, Mo., told Reuters Health by email. “It takes additional… [Read More]
Vaccines and Biologics: What Rheumatologists Need to Know

How vaccines, medications and rheumatic disease-related effects on immune system interact... [Read More]
ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs... [Read More]
A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease

PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases… [Read More]
The State of Clinical Research in Vasculitis: 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab… [Read More]
How to Watch for Immune Deficiencies & Manage Risk

CHICAGO—When a patient with rheumatic disease suffers recurrent infections, has a history of multiple autoimmune diseases or presents with atypical autoimmune syndromes, clinicians should consider the possibility of an immune deficiency, an expert said at the ACR State-of-the-Art Clinical Symposium in April. W. Winn Chatham, MD, professor of medicine at the University of Alabama at… [Read More]